229 related articles for article (PubMed ID: 11182745)
21. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.
Antonelli A; Rotondi M; Fallahi P; Romagnani P; Ferrari SM; Barani L; Ferrannini E; Serio M
Clin Endocrinol (Oxf); 2006 Feb; 64(2):189-95. PubMed ID: 16430719
[TBL] [Abstract][Full Text] [Related]
22. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period.
Carella C; Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Nersita R; Iorio S; Amato G; Braverman LE; Roti E
Thyroid; 2006 Mar; 16(3):295-302. PubMed ID: 16571093
[TBL] [Abstract][Full Text] [Related]
23. Correlation of orbital muscle changes evaluated by magnetic resonance imaging and thyroid-stimulating antibody in patients with Graves' ophthalmopathy.
Nishikawa M; Yoshimura M; Toyoda N; Masaki H; Yonemoto T; Gondou A; Kato T; Kurokawa H; Furumura T; Inada M
Acta Endocrinol (Copenh); 1993 Sep; 129(3):213-9. PubMed ID: 8105634
[TBL] [Abstract][Full Text] [Related]
24. Ultrasonographic thyroid volume as a reliable prognostic index of radioiodine-131 treatment outcome in Graves' disease hyperthyroidism.
Gómez-Arnaiz N; Andía E; Gumà A; Abós R; Soler J; Gómez JM
Horm Metab Res; 2003 Aug; 35(8):492-7. PubMed ID: 12953167
[TBL] [Abstract][Full Text] [Related]
25. TSH-receptor antibodies may prevent bone loss in pre- and postmenopausal women with Graves' disease and Graves' orbitopathy.
Siderova M; Hristozov K; Tsukeva A
Arch Endocrinol Metab; 2018; 62(2):221-226. PubMed ID: 29768627
[TBL] [Abstract][Full Text] [Related]
26. Retrobulbar ocular blood flow changes after orbital decompression in Graves' ophthalmopathy measured by color Doppler imaging.
Pérez-López M; Sales-Sanz M; Rebolleda G; Casas-Llera P; González-Gordaliza C; Jarrín E; Muñoz-Negrete FJ
Invest Ophthalmol Vis Sci; 2011 Jul; 52(8):5612-7. PubMed ID: 21498614
[TBL] [Abstract][Full Text] [Related]
27. Standardized grey scale ultrasonography in Graves' disease: correlation to autoimmune activity.
Schiemann U; Gellner R; Riemann B; Schierbaum G; Menzel J; Domschke W; Hengst K
Eur J Endocrinol; 1999 Oct; 141(4):332-6. PubMed ID: 10526244
[TBL] [Abstract][Full Text] [Related]
28. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.
Eckstein AK; Plicht M; Lax H; Hirche H; Quadbeck B; Mann K; Steuhl KP; Esser J; Morgenthaler NG
Clin Endocrinol (Oxf); 2004 Nov; 61(5):612-8. PubMed ID: 15521965
[TBL] [Abstract][Full Text] [Related]
29. Effect of steroid pulse therapy with and without orbital radiotherapy on Graves' ophthalmopathy.
Ohtsuka K; Sato A; Kawaguchi S; Hashimoto M; Suzuki Y
Am J Ophthalmol; 2003 Mar; 135(3):285-90. PubMed ID: 12614743
[TBL] [Abstract][Full Text] [Related]
30. High Titers of Thyrotropin Receptor Antibodies Are Associated With Orbitopathy in Patients With Graves Disease.
Kahaly GJ; Wüster C; Olivo PD; Diana T
J Clin Endocrinol Metab; 2019 Jul; 104(7):2561-2568. PubMed ID: 30753531
[TBL] [Abstract][Full Text] [Related]
31. Ultrasound measurement of the horizontal external eye muscles in patients with thyroid disease. Is orbital involvement associated with thyroid autoantibodies?
Zimmermann-Belsing T; Feldt-Rasmussen U; Fledelius H
Eur J Ophthalmol; 2002; 12(5):351-8. PubMed ID: 12474915
[TBL] [Abstract][Full Text] [Related]
32. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study.
Glinoer D; de Nayer P; Bex M;
Eur J Endocrinol; 2001 May; 144(5):475-83. PubMed ID: 11331213
[TBL] [Abstract][Full Text] [Related]
33. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage.
Chiovato L; Fiore E; Vitti P; Rocchi R; Rago T; Dokic D; Latrofa F; Mammoli C; Lippi F; Ceccarelli C; Pinchera A
J Clin Endocrinol Metab; 1998 Jan; 83(1):40-6. PubMed ID: 9435414
[TBL] [Abstract][Full Text] [Related]
34. Thyroid vascularization by color doppler ultrasonography in Graves' disease. Changes related to different phases and to the long-term outcome of the disease.
Baldini M; Castagnone D; Rivolta R; Meroni L; Pappalettera M; Cantalamessa L
Thyroid; 1997 Dec; 7(6):823-8. PubMed ID: 9459623
[TBL] [Abstract][Full Text] [Related]
35. Behavior of soluble intercellular adhesion molecule-1 and endothelial-leukocyte adhesion molecule-1 concentrations in patients with Graves' disease with or without ophthalmopathy and in patients with toxic adenoma.
De Bellis A; Bizzarro A; Gattoni A; Romano C; Di Martino S; Sinisi AA; Abbadessa S; Bellastella A
J Clin Endocrinol Metab; 1995 Jul; 80(7):2118-21. PubMed ID: 7541801
[TBL] [Abstract][Full Text] [Related]
36. Changes in graves' ophthalmopathy after radioiodine and anti-thyroid drug treatment of Graves' disease from 2 prospective, randomized, open-label, blinded end point studies.
Chen DY; Schneider PF; Zhang XS; Luo XY; He ZM; Chen TH
Exp Clin Endocrinol Diabetes; 2014 Jan; 122(1):1-6. PubMed ID: 24203649
[TBL] [Abstract][Full Text] [Related]
37. Current perspective on the pathogenesis of Graves' disease and ophthalmopathy.
Prabhakar BS; Bahn RS; Smith TJ
Endocr Rev; 2003 Dec; 24(6):802-35. PubMed ID: 14671007
[TBL] [Abstract][Full Text] [Related]
38. Thyroid hypoechogenicity after methimazole withdrawal in Graves' disease: a useful index for predicting recurrence?
Zingrillo M; D'Aloiso L; Ghiggi MR; Di Cerbo A; Chiodini I; Torlontano M; Liuzzi A
Clin Endocrinol (Oxf); 1996 Aug; 45(2):201-6. PubMed ID: 8881453
[TBL] [Abstract][Full Text] [Related]
39. Thyrotropin receptor antibodies in hypothyroid Graves' disease.
Kasagi K; Hidaka A; Nakamura H; Takeuchi R; Misaki T; Iida Y; Konishi J
J Clin Endocrinol Metab; 1993 Feb; 76(2):504-8. PubMed ID: 8094394
[TBL] [Abstract][Full Text] [Related]
40. Serum antibodies to collagen XIII: a further good marker of active Graves' ophthalmopathy.
De Bellis A; Sansone D; Coronella C; Conte M; Iorio S; Perrino S; Battaglia M; Bellastella G; Wall JR; Bellastella A; Bizzarro A
Clin Endocrinol (Oxf); 2005 Jan; 62(1):24-9. PubMed ID: 15638866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
